Magnesium-28: A theorical novel self-theranostic strategy targeting metabolic enzyme disruption and intracellular irradiation

The limitations of conventional cancer therapies, such as low selectivity and significant side effects, necessitate innovative approaches. This study proposes a pioneering self-theranostic strategy using magnesium-28 (Mg-28) alone, enabling simultaneous diagnosis, therapy, and treatment monitoring. Exploiting the elevated Mg ion demand in cancer cells, Mg-28 selectively targets Mg-dependent enzymes (e.g., DNA/RNA polymerases, hexokinase, telomerase) within intracellular organelles, such as the nucleus and mitochondria, without requiring biochemical carriers or nanoparticles, as in recent methods. A theoretical model based on the Mg-uptake coefficient predicts selective Mg-28 accumulation in tumors following intravenous administration. The Mg-28 decay chain—progressing through Aluminum-28 to stable Silicon-28—delivers highly localized irradiation through beta particles, Auger electrons, and recoil ions to critical intracellular structures, while simultaneously disrupting essential Mg-dependent enzymes. This results in a dual mechanism of radiotherapy and multi-enzyme inactivation. Simulations of linear energy transfer, radiation range, and absorbed dose show that nanogram-scale amounts of Mg-28 can deliver 60–400 Gy to tumors ranging from 0.03 mg to 500 g, suggesting potent cytotoxicity across a broad range of tumor sizes and stages. This potential is grounded in the universal metabolic reliance of cancer cells on Mg. Moreover, gamma emissions from Mg-28 and its daughter isotopes support early tumor detection and real-time treatment monitoring, enhancing therapeutic precision. As the first proposed single-isotope theranostic approach leveraging Mg dependency, this innovative strategy provides a robust foundation for future pre-clinical and clinical investigations aimed at validating its therapeutic efficacy, pharmacokinetics, and biosafety—thereby inaugurating a novel hypothesis for cancer therapy.

Authors

Publication Details

Journal
Tumor Discovery
Published
2025-08-13
DOI
https://doi.org/10.36922/td025070010
Citations
1
Primary Topic
Chemical Reactions and Isotopes
Type
article
Field-Weighted Citation Impact
0.79
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Magnesium-28: A theorical novel self-theranostic strategy targeting metabolic enzyme disruption and intracellular irradiation

Tran Van Luyen
1 citations
Tumor Discovery
Chemical Reactions and Isotopes
0.79
article

Magnesium-28: A theorical novel self-theranostic strategy targeting metabolic enzyme disruption and intracellular irradiation

Tran Van Luyen
article en
1 citations

Abstract

The limitations of conventional cancer therapies, such as low selectivity and significant side effects, necessitate innovative approaches. This study proposes a pioneering self-theranostic strategy using magnesium-28 (Mg-28) alone, enabling simultaneous diagnosis, therapy, and treatment monitoring. Exploiting the elevated Mg ion demand in cancer cells, Mg-28 selectively targets Mg-dependent enzymes (e.g., DNA/RNA polymerases, hexokinase, telomerase) within intracellular organelles, such as the nucleus and mitochondria, without requiring biochemical carriers or nanoparticles, as in recent methods. A theoretical model based on the Mg-uptake coefficient predicts selective Mg-28 accumulation in tumors following intravenous administration. The Mg-28 decay chain—progressing through Aluminum-28 to stable Silicon-28—delivers highly localized irradiation through beta particles, Auger electrons, and recoil ions to critical intracellular structures, while simultaneously disrupting essential Mg-dependent enzymes. This results in a dual mechanism of radiotherapy and multi-enzyme inactivation. Simulations of linear energy transfer, radiation range, and absorbed dose show that nanogram-scale amounts of Mg-28 can deliver 60–400 Gy to tumors ranging from 0.03 mg to 500 g, suggesting potent cytotoxicity across a broad range of tumor sizes and stages. This potential is grounded in the universal metabolic reliance of cancer cells on Mg. Moreover, gamma emissions from Mg-28 and its daughter isotopes support early tumor detection and real-time treatment monitoring, enhancing therapeutic precision. As the first proposed single-isotope theranostic approach leveraging Mg dependency, this innovative strategy provides a robust foundation for future pre-clinical and clinical investigations aimed at validating its therapeutic efficacy, pharmacokinetics, and biosafety—thereby inaugurating a novel hypothesis for cancer therapy.

Tumor DiscoveryVol. 4(3)
Openalex Percentile: Top 24%
Chemical Reactions and Isotopes
0.79
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Magnesium-28: A theorical novel self-theranostic strategy targeting metabolic enzyme disruption and intracellular irradiation — Tran Van Luyen · Tumor Discovery (2025) | TGRS Research Map | TGRS